Compared side by side

Tirzepatide vs dulaglutide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Dulaglutide activates one receptor, GLP-1; tirzepatide activates GLP-1 and GIP. Both are weekly shots with half-lives of about 5 days, and both are FDA-approved for type 2 diabetes, dulaglutide as Trulicity and tirzepatide as Mounjaro; only tirzepatide is approved for weight management, as Zepbound. Dulaglutide’s effect on weight is modest, about 1 to 5 kg on average in its diabetes trials, and tirzepatide’s 15 mg produced up to 22.5% weight loss at 72 weeks (SURMOUNT-1).

Side by side

ComparedTirzepatideDulaglutide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asMounjaro, Zepbound, LY3298176Trulicity, LY2189265, Dula
What it isThe first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).A weekly GLP-1 pen (Trulicity) for type 2 diabetes: it lowers blood sugar and, in people at cardiovascular risk, the combined risk of heart attack, stroke and cardiovascular death, and it comes in four ready-dosed pens.
How it worksDual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.GLP-1 receptor agonist made as a fusion protein: two GLP-1 analogue chains, 90% the same as human GLP-1, joined to the Fc fragment of a modified IgG4 antibody (about 63 kDa). It releases insulin when glucose is high, lowers glucagon and slows stomach emptying. Its large Fc-fusion design slows its clearance, to a half-life of about 5 days, which makes it a weekly shot. FDA-approved in 2014 for type 2 diabetes (adults, and children 10 and older) and to lower major cardiovascular events in adults with type 2 diabetes and heart disease or its risk factors; it is not approved for weight management.
Commonly reportedVery strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).Steadier glucose readings and, for some, a smaller appetite, with nausea or loose stools mostly in the first weeks and after a step-up. FDA-approved since 2014, with more than a decade of use behind it.
Studied rangeFDA label: 2.5–15 mg, starting dose 2.5 mg.FDA label: 0.75–4.5 mg, starting dose 0.75 mg.
How oftenWeeklyWeekly
Half-life~5 days (FDA label)~5 days (FDA label)
RouteSubQ injectionSubQ injection
Typical runFDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.FDA-approved for ongoing use; its heart-outcomes trial followed people for a median of 5.4 years. The 3 and 4.5 mg steps are optional, for more glucose control.
EvidenceEstablished: clinical trials or FDA-approved use existsEstablished: clinical trials or FDA-approved use exists
Common side effectsNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigueNausea, diarrhea, vomiting, abdominal pain, decreased appetite, indigestion, fatigue

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide or dulaglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Tirzepatide

  • Day 1–28 · 2.5 mg Getting your gut acclimated
  • Day 29–56 · 5 mg First therapeutic dose — weight drops
  • Day 57–112 · 7.5 mg Dual agonism in full effect
  • Day 113–168 · 12.5 mg Max titration reached
  • Day 169–504 Weeks 24 to 72: where most people plateau
  • Day 365+ A maintenance medication, not a course

Every card for tirzepatide, with its sources

Dulaglutide

  • Day 1–28 · 0.75 mg The 0.75 mg start
  • Day 29–364 · 1.5 mg 1.5 mg, the dose of its heart trial
  • Day 57–364 · 3 mg 3 mg, a step for more glucose control
  • Day 85–364 · 4.5 mg 4.5 mg, the top dose
  • Day 365+ A long-term medicine, not a course

Every card for dulaglutide, with its sources

Questions people ask

How long do tirzepatide and dulaglutide last?

The half-life of tirzepatide is ~5 days (FDA label). The half-life of dulaglutide is ~5 days (FDA label).

How often are tirzepatide and dulaglutide taken?

Tirzepatide: weekly. Route: SubQ injection. Dulaglutide: weekly. Route: SubQ injection.

How are tirzepatide and dulaglutide dosed in research?

The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose. The FDA label range for dulaglutide is 0.75–4.5 mg, with a 0.75 mg starting dose.

What are the common side effects of tirzepatide and dulaglutide?

For tirzepatide, the library lists: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue. For dulaglutide: nausea, diarrhea, vomiting, abdominal pain, decreased appetite, indigestion, fatigue.

Each one in full

Track it in the app

PepVault for iPhone

Taking tirzepatide or dulaglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo